Investment Thesis
Roivant Sciences is a pre-revenue stage pharmaceutical company with minimal revenue ($5.7M) and massive operating losses (-$930.3M), burning cash at an unsustainable rate of -$593.5M annually in free cash flow. While the company maintains a strong balance sheet with $1.5B in cash and low debt (0.07x D/E), this provides only ~2.5 years of runway at current burn rates with no visible path to profitability or commercial viability.
Strengths
- Strong liquidity position with $1.5B in cash and 30.66x current ratio
- Conservative capital structure with minimal debt (Debt/Equity 0.07x) and low financial risk
- Solid equity base of $4.3B providing balance sheet cushion for continued operations
Risks
- Unsustainable cash burn of -$593.5M annually will deplete cash reserves within 2-3 years without material revenue growth
- Revenue base of only $5.7M with -11.2% YoY decline indicates failed commercialization efforts or non-viable product portfolio
- Massive operating losses (-$930.3M) and negative operating margin of -16,207.5% demonstrate fundamental operational failure to generate revenue from cost structure
- No evidence of near-term catalysts for profitability or successful drug development in provided data
Key Metrics to Watch
- Revenue growth rate and pipeline advancement toward FDA approvals
- Quarterly cash burn rate and months of cash runway remaining
- Operating expense reduction initiatives and path to operating break-even
Financial Metrics
Revenue
5.7M
Net Income
-602.8M
EPS (Diluted)
$-0.88
Free Cash Flow
-593.5M
Total Assets
5.2B
Cash
1.5B
Profitability Ratios
Gross Margin
N/A
Operating Margin
-16,207.5%
Net Margin
-10,501.1%
ROE
-14.1%
ROA
-11.5%
FCF Margin
-10,339.4%
Balance Sheet & Liquidity
Current Ratio
30.66x
Quick Ratio
30.44x
Debt/Equity
0.07x
Debt/Assets
4.8%
Interest Coverage
-69.43x
Long-term Debt
311.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T07:10:20.837090 |
Data as of: 2025-12-31 |
Powered by Claude AI